Lilly-Backed China Startup Debuts With $68.7M Seed to Advance Next-Gen T Cell Engagers

Why It Matters

The sizable seed investment validates confidence in next‑generation T‑cell therapies and signals China’s emergence as a hub for accelerated immuno‑oncology development.

Key Takeaways

• $68.7M seed round led by global and Chinese investors
• Tri‑specific antibodies target DLL3, CD3, 4‑1BB
• EXP011 entered Phase 1/2 trial October 2025
• Proprietary platforms aim at undruggable targets
• China’s biotech speed attracts major pharma capital

Pulse Analysis

Excalipoint Therapeutics’ $68.7 million seed financing marks a watershed moment for China’s emerging immuno‑oncology sector. Backed by a blend of domestic and international investors—including Lilly Asia Ventures and Eisai Innovation—the round underscores a growing appetite for high‑risk, high‑reward cell‑engager platforms. By securing capital at the seed stage, Excalipoint can accelerate pre‑clinical validation and clinical enrollment for its six pipeline candidates, positioning itself to compete with established Western biotech firms that are also eyeing China’s fast‑track development environment.

At the scientific core of Excalipoint’s strategy are tri‑specific antibodies that simultaneously engage tumor antigens, CD3 on T‑cells, and co‑stimulatory 4‑1BB receptors. This design promises enhanced tumor specificity and sustained T‑cell activation, potentially overcoming resistance mechanisms that limit current bispecific therapies. The company’s flagship candidate, EXP011, targets DLL3—a marker prevalent in small‑cell lung and neuroendocrine tumors—while other assets like EXP012 aim at gastrointestinal malignancies. Complementary technologies such as TOPAbody, T‑Cell Immune Shield, and TCE Probody are intended to broaden the addressable target space, including proteins previously deemed undruggable, thereby expanding therapeutic options for patients with unmet needs.

The broader market context amplifies Excalipoint’s relevance. Recent McKinsey analysis highlights China’s ability to compress drug development timelines by 50‑70 % thanks to parallelized workflows, dense CRO networks, and a large patient pool. This efficiency has already attracted multibillion‑dollar commitments from AstraZeneca, Novartis, Roche, and Pfizer, signaling a strategic shift toward Chinese clinical sites. Excalipoint’s launch, therefore, not only adds a promising pipeline to the global T‑cell engager landscape but also exemplifies how Chinese biotech firms are leveraging capital, talent, and regulatory reforms to become pivotal players in the next wave of cancer therapeutics.